Descovy (Emtricitabine/Tenofovir alafenamide) for HIV

Overview
Descovy is a prescription drug approved by the Food and Drug Administration (FDA) as a treatment to be used in combination with other retroviral agents for HIV-1 infection in adults and children over 12 years of age. Descovy is a combination drug composed of Emtricitabine and Tenofovir alafenamide, which are also known respectively by the abbreviations FTC and TAF. Emtricitabine and Tenofovir alafenamide are both antiretroviral medications of the nucleoside reverse transcriptase inhibitor (NRTI) class. NRTI drugs are believed to work by preventing HIV from replicating in cells.

How do I take it?
Prescribing information states that Descovy is taken once daily. Descovy comes in tablet form.

Side effects
The FDA-approved label for Descovy lists common side effects including nausea. Rare but serious side effects listed for Descovy include lactic acidosis (a metabolic disorder), severe exacerbation of Hepatitis B, kidney problems, a decrease in bone mineral density, and immune reconstitution syndrome (new or returning infections).

For more details about this treatment, visit:

Descovy – Gilead

Overview of HIV Treatments – AIDS.gov